Brind.
  1. Immutep's clinical trial utilized MSD's anti-PD-1 drug, and the FDA provided positive feedback regarding the potential for treatment development.

Immutep reports activities from Sydney, Australia.

2 reports, 2 independent Updated Jul 30
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Immutep reports activities from Sydney, Australia.

Who's involved

What this event is mainly about
Immutep

Keep exploring

Part of

Immutep's clinical trial utilized MSD's anti-PD-1 drug, and the FDA provided positive feedback regarding the potential for treatment development. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireImmutep Quarterly Activities Report Q4 FY25 Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patie
  • Simply Wall St.3 ASX Penny Stocks With Market Caps Under A$400M To Watch The Australian stock market showed mixed performance recently, with utilities and energy sectors leading gains while financials lagged behind